RetaCalc
Protocol library
SingleNot ApprovedMixedLow confidenceSourced

GHK-Cu

A copper-binding tripeptide investigated mainly in laboratory, wound and topical cosmetic contexts. Evidence does not establish an injectable human regimen.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Community-reported schedule

Community-reported · not a validated schedule

Community dose schedule

Two community-provenance subcutaneous lines - an Anela-derived daily dose co-formulated with BPC-157 near 1-1.75 mg, and an educational 50 mg-vial titration to 2 mg. Community reports only, not a validated or trial-verified schedule.

Evidence source
Reported maximum quantityChoose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.

Reported quantities by phase

Select a point for its calculation examples
  1. Starting (SubQ + BPC-157)
    1 mg
    BPC-157 co-formulation is treated as near-mandatory because pure GHK-Cu causes severe injection-site reactions; the Anela mix is 50 mg GHK-Cu + 10 mg BPC-157 in 3 mL.
  2. Steady (preferred)
    1.75 mg
    +0.75 mg
    Community practice spans about 1-3 mg daily, cycled roughly six months with a daily zinc supplement.

Vial-aware arithmetic

Reconstitution examples, up to 3 mL

Choose the vial quantity and BAC water first. The diagram and results below update for the selected 1 mg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.

Vial quantity

Choose the quantity printed on the vial.

BAC water added

Use 1, 2 or 3 mL, or enter a custom volume up to 3 mL.

Open the full reverse calculator
Three millilitre research vial, diluent vial and capped U-100 syringe on an ink-blue surface
One small vial, one measured diluent volume and one U-100 scale. The arithmetic connects all three.
BAC water selected
3 mL

Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.

1 mL BAC
2 units

resulting U-100 draw

Concentration
50 mg/mL
BAC added
1 mL
2 mL BAC
4 units

resulting U-100 draw

Concentration
25 mg/mL
BAC added
2 mL
3 mL BAC
6 units

resulting U-100 draw

Concentration
16.667 mg/mL
BAC added
3 mL

Shown in the diagram. Closest of these examples to 25 units.

Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Evidence Gap
Published laboratory, wound-healing and cosmetic research populations

Formulations and exposure varied substantially across the cited literature

No evidence-backed injectable schedule is presented because the reviewed literature does not establish one.

View source
Community GuideSubcutaneous in guideFive days per week
Third-party educational schedule for a 50 mg research vial

1 mg per administration in weeks 1-4, 1.5 mg in weeks 5-8 and 2 mg in weeks 9-12, five days per week

This proposed subcutaneous schedule is not validated by the topical, wound or laboratory human literature and is shown only as low-confidence provenance.

View source
Community GuideSubcutaneous or topical in reportsDaily or five days weekly in reports
online research community summaries and reports

The spotlight states 2-5 mg per subcutaneous administration and 1 gram per ounce topically, while common injection reports include 2 mg Monday-Friday

The channel itself says useful human subcutaneous dosing trials are absent. Daily reports extend above the commercial guide and blend quantities vary substantially; raw/peptide-education/pe-ghk-cu.md:24-31, 1047-1053 and 2605-2609.

View source
Community GuideSubcutaneous, co-formulated with BPC-157, in reportsDaily; cycled about six months
authenticated research-forum (Peppys) reports and an Official Anela protocol

A flagship injectable protocol reconstitutes 50 mg GHK-Cu with 10 mg BPC-157 in 3 mL bacteriostatic water and doses roughly 1-1.75 mg GHK-Cu subcutaneously per injection (the author prefers 1.75 mg, about 10.5 units); community practice sits around 1-3 mg daily, with a cited upper limit near 33 mg daily, cycled about six months with daily zinc; a separate 2 percent topical serum is used twice daily

Forum provenance from an authenticated archive with usernames omitted. Co-formulation with BPC-157 is treated as near-mandatory because pure GHK-Cu causes severe injection-site reactions. The injectable, topical serum and cream routes are kept separate rather than interconverted, and quantities conflict. Community provenance, not controlled human dose finding.

View source

Evidence summary

GHK-Cu is discussed across cell, animal, wound and cosmetic research. Route and formulation matter, and topical findings cannot be converted into an injection protocol.

Protocol status

RetaCalc deliberately withholds an injectable studied-regimen table until suitable controlled human evidence supports one.

Community provenance (Peppys)

An authenticated research-forum archive, including an Official Anela protocol, records a subcutaneous injectable that reconstitutes 50 mg GHK-Cu with 10 mg BPC-157 in 3 mL and doses roughly 1-1.75 mg per injection, with the co-formulated BPC-157 treated as near-mandatory to control severe injection-site reactions. Community practice is described around 1-3 mg daily, cycled about six months with daily zinc, alongside a separate 2 percent topical serum applied twice daily. The archive keeps the injectable, serum and cream routes separate and records conflicting quantities up to a cited 33 mg daily ceiling; usernames are omitted and figures are logged as community provenance without endorsement. The planner above reproduces the arithmetic of the injectable reports only and does not validate them.

Warnings and contraindications

Topical or laboratory findings do not establish safety for injection.
Copper exposure and product-specific formulation require separate assessment.
Organised research bench with labelled storage tray, vial rack, notebook and thermometer
A clean workspace supports traceability. It does not establish sterility.

Shared across protocols

Supplies and general handling

Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.

Research vial

Select the labelled vial quantity used in the calculation.

View Peppys vial

Bacteriostatic water

Use only a diluent appropriate to the research method and formulation.

View Peppys BAC water

U-100 measuring syringe

Use a new sterile device for every entry. Source locally.

Source locally

Wipes and sharps container

Plan clean handling and immediate sharps disposal. Source locally.

Source locally

Storage follows the label

Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.

Use sterile equipment once

CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.

Stability is formulation-specific

Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.

General references: CDC injection safety, NHS medicine storage and DailyMed BAC water labelling.